Sotagliflozin with insulin for treating type 1 diabetes

  • Technology appraisal guidance
  • TA622
  • Published: 

NICE has withdrawn this guidance. This is because the company is no longer marketing sotagliflozin (Zynquista) and its marketing authorisation has been withdrawn.